RAR-related orphan receptor-gt (ROR-gt) directs differentiation of proinflammatory T helper 17 (T H 17) cells and is a potential therapeutic target in chronic autoimmune and inflammatory diseases [1] [2] [3] . However, ROR-gt-dependent group 3 innate lymphoid cells ILC3s provide essential immunity and tissue protection in the intestine [4] [5] [6] [7] [8] [9] [10] [11] , suggesting that targeting RORgt could also result in impaired host defense after infection or enhanced tissue damage. Here, we demonstrate that transient chemical inhibition of ROR-gt in mice selectively reduces cytokine production from T H 17 but not ILCs in the context of intestinal infection with Citrobacter rodentium, resulting in preserved innate immunity. Temporal deletion of Rorc (encoding ROR-gt) in mature ILCs also did not impair cytokine response in the steady state or during infection. Finally, pharmacologic inhibition of ROR-gt provided therapeutic benefit in mouse models of intestinal inflammation and reduced the frequency of T H 17 cells but not ILCs isolated from primary intestinal samples of individuals with inflammatory bowel disease (IBD). Collectively, these results reveal differential requirements for ROR-gt in the maintenance of T H 17 cell and ILC3 responses and suggest that transient inhibition of ROR-gt is a safe and effective therapeutic approach during intestinal inflammation.
Although therapeutic targeting of the T H 17 cell pathway is effective in several autoimmune diseases [12] [13] [14] , in Crohn's disease blockade of interleukin 17A (IL-17A) is ineffective and, in some cases, associated with worsened disease or increased opportunistic infections [15] [16] [17] . This is consistent with mouse models demonstrating protective functions for IL-17A and the (often coexpressed) cytokine IL-22 in the intestine [18] [19] [20] [21] [22] [23] , mediated in part by ROR-γt + ILC3s [4] [5] [6] [7] [8] [9] [10] [11] . Smallmolecular-weight inhibitors of ROR-γt offer an alternative therapeutic approach, with several identified and found to show efficacy in models of autoimmunity [24] [25] [26] [27] [28] . However, the effect of targeting ROR-γt in intestinal immune cells remains unexplored.
To investigate the impact of ROR-γt inhibitors in the intestine, we infected C57BL/6 mice with the enteric pathogen Citrobacter rodentium, which elicits ROR-γt + T H 17 cell and ILC3 responses 6, 7, 29, 30 , then treated them with a vehicle control or GSK805, an orally available inhibitor of ROR-γt-mediated transcription 24 . Compared to the vehicle control, oral GSK805 treatment reduced the frequency and total number of IL-17A-and IL-22-producing T H 17 cells, but not IFN-γ + T H 1 cells, in the colon lamina propria (cLP) and mesenteric lymph node (mLN; Fig. 1a,d,e) . In contrast, GSK805 treatment did not alter the percentage or total number of IL-17A-or IL-22-producing ILC3s in the colon or mLN (Fig. 1b,c,f) . IL-22 production from ILC3s or T cells mediates protective immunity to C. rodentium at early or late stages of infection, respectively 6, 7, 29 . Consistent with this, GSK805-and control-treated mice showed similar C. rodentium burdens during early infection, but GSK805-treated mice had higher levels at later stages (Supplementary Fig. 1a) . Preserved innate immunity allowed 75% survival in GSK805-treated mice at day 20 after infection, whereas mice administered anti-IL-23 monoclonal antibody showed 100% mortality at that time point (Fig. 1g) owing to inhibition of ILC3 and T H 17 cell responses 7, 23, 30 . GSK805-treated mice showed increased colon length (Fig. 1h) , fewer histological signs of inflammation and tissue damage (Fig. 1i) than controls. In response to a systemic infection with the opportunistic pathogen Candida albicans, vehicle-treated controls and GSK805-treated mice had similar IL-17A + ILC3 responses in the spleen, fungal burdens and low levels of inflammation in the kidney, whereas Il17a −/− mice showed significantly increased fungal burdens and kidney inflammation (P < 0.05, Supplementary Fig. 1b-d) .
Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing T H 17 cells and preserving group 3 innate lymphoid cells
To further define the requirements for ROR-γt in the maintenance of ILC3 responses, we generated mice in which Rorc (encoding ROR-γt) can be temporally deleted in mature ILC3s. This was accomplished by crossing mice carrying loxP-flanked Rorc (Rorc flox ) with Id2 CreERT2 mice, in which Cre recombinase activity is targeted to innate lymphoid cells (ILCs) after tamoxifen administration (Supplementary Fig. 2a) , to generate Id2 i∆ROR-γt mice. After 2 weeks of tamoxifen administration, we observed similar frequencies of total ILCs (lineage − (Lin − ) CD127 + cells) in the mLN of control and Id2 i∆ROR-γt mice, with efficient deletion of ROR-γt protein (Fig. 2a) . Despite the loss of ROR-γt, analyses of total ILCs in the mLNs of (Rorc flox ) control and Id2 i∆ROR-γt mice showed similar frequencies of cells with an ILC3-like phenotype, including those expressing the chemokine receptor CCR6, cluster of differentiation 4 (CD4) and major histocompatibility complex class II (MHC-II) (Fig. 2b,c) . Further, microarray analyses of sort-purified CCR6 + ILCs (gated as Lin − CD127 + CCR6 + ) revealed fewer Rorc transcripts in Id2 i∆ROR-γt mice given tamoxifen than in Rorc flox mice but similar expression levels of other genes associated with ILC3 function (Fig. 2d) . To determine how long ILC3-like cells could persist in the absence of Rorc, we administered 6-week-old Id2 i∆ROR-γt and Rorc flox mice tamoxifen continuously for 12 weeks. At this time point, we observed cells with an ILC3-like phenotype in the mLN of Id2 i∆ROR-γt mice, and modest changes in absolute cell numbers and surface markers ( Supplementary Fig. 3 ). In contrast, an ILC3-like population was not maintained in the small intestine, but an increase in the numbers of Lin − CD127 + NKp46 + ILC1-like cells was evident ( Supplementary Fig. 4 ). These results suggest that prolonged loss of ROR-γt may cause an expansion of ILC3s that have lost expression of ROR-γt (ex-ILC3s) or ILC1s in the small intestine [31] [32] [33] or a loss of proinflammatory ILC3s 34, 35 . Consistent with a loss in proinflammatory ILC3s, we observed a decrease in IFN-γ + ILCs in the small intestine but no change in the mLN at the 12 week time point (Supplementary Fig. 4 ).
Despite these changes in the intestine, we observed similar frequencies and numbers of ROR-γt − ILCs that were able to produce IL-17A and IL-22 in the mLN of Id2 i∆ROR-γt mice and Rorc flox mice after 12 weeks of continuous tamoxifen administration ( Supplementary Fig. 4 ).
Consistent with a preservation of ILC3 function, tamoxifenadministered Rorc flox control and Id2 i∆ROR-γt mice showed similar frequencies of IL-17A + ILC3s in the spleen and colony-forming units (CFU) of C. albicans in the kidney, as well as a lack of inflammation in the kidney after infection (in contrast to results in Il17a −/− mice) ( Supplementary Fig. 2b,c) . Furthermore, Rorc flox and Id2 i∆ROR-γt mice showed similar frequencies of IL-22 + ILC3s in the mLN after C. rodentium infection (Fig. 2e) . To compare these results to transient genetic deletion of ROR-γt in CD4 + T cells, we crossed Rorc flox mice to Cd4 CreERT2 mice to generate CD4 i∆ROR-γt mice. IL-17A production was lower in CD4 + T cells from the mLN of CD4 i∆ROR-γt mice administered tamoxifen and infected with C. rodentium than in those of littermate controls (Fig. 2f) , demonstrating differential requirements for ROR-γt between ILC3s and T H 17 cells. Further, 75% of Id2 i∆ROR-γt mice survived to day 20 after infection with C. rodentium, compared to Rorc −/− mice, which have impaired ILC3 and T H 17 cell development and showed 100% mortality (Fig. 2g) . CD4 i∆ROR-γt mice exhibited mortality at later stages of infection with C. rodentium (Fig. 2g) but showed increased colon length (Fig. 2h) and reduced histological signs of intestinal inflammation (Fig. 2i) relative to control and Id2 i∆ROR-γt mice, suggesting that although T H 17 cells are important for immunity at late stages of infection, they are also primary mediators of intestinal damage and inflammation.
Previous studies have reported a low turnover rate of ILC3s 36 , and pulse-chase experiments with tamoxifen administration in Id2 i∆ROR-γt mice revealed differing half-lives of ILC3s in the mLN and intestine (Supplementary Fig. 5) . Further, in all tissues assessed, markers of proliferation were higher in T H 17 cells than in ILC3s at Fig. 6 ). However, this did not account for the differential requirements of sustained ROR-γt expression, as treatment of mice with complexes of IL-2 and anti-IL-2 induced ILC3 proliferation (Supplementary Fig. 7) and expanded a population of the ROR-γt − ILC3s in the mLN of tamoxifentreated Id2 i∆ROR-γt mice, which produced similar levels of IL-17A and IL-22 relative to ROR-γt + ILC3s in control (Rorc flox ) mice (Supplementary Fig. 8 ).
To experimentally address whether chemical inhibition of ROR-γt can provide therapeutic benefit in the context of intestinal inflammation, we administered vehicle or GSK805 to Il10 −/− mice aged 10 weeks (when spontaneous colonic inflammation is observed) at a dose 10 mg per kg of body weight per day (mg/kg/d) for 2 weeks. GSK805 administration reduced the frequency of IL-17A + T H 17 cells in the colonic tissues but had no effect on the frequency of IL-17A + ILC3s (Fig. 3a) . Furthermore, GSK805 treatment reduced amounts of Error bars, mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test).
npg fecal lipocalin-2 (Fig. 3b) , prevented shortening of the colon (Fig. 3c) and reduced histological signs of inflammation in the colon (Fig. 3d) of Il10 −/− mice, relative to controls. In a second model of intestinal inflammation, we transferred CBir1-transgenic CD4 + T cells, which recognize an immunodominant and commensal bacteria-derived antigen in Crohn's disease 37 , into Rag1 −/− mice. At 2 weeks after transfer, we observed intestinal inflammation; we then treated mice orally with either vehicle control or GSK805 (10 mg/kg/d) for 2 weeks. GSK805 treatment significantly reduced the frequency of colonic CBir1-specific T H 17 cells but not IL-17A + ILC3s (P < 0.01, Fig. 3e ). GSK805 treatment also reduced fecal lipocalin-2, colonic shortening and histological signs of inflammation in the colons of Rag1 −/− mice receiving a CBir1 T cell transfer, relative to control mice (Fig. 3f-h) . Together, these results demonstrate that transient inhibition of ROR-γt provides therapeutic benefit in the context of two mouse models of intestinal inflammation.
To investigate how transient inhibition of ROR-γt modulates human T H 17 cell and ILC3 responses, we obtained colonic resection tissues from pediatric individuals with Crohn's disease, digested them and cultured single-cell suspensions for 12 h in the presence of DMSO (control) or GSK805. ILC3s were identified by gating on Lin − cells and examining for CD127 + populations (Fig. 4a) followed by coexpression of natural killer cell receptor NKp44 and stem cell factor receptor c-Kit. Compared to control (DMSO), incubation with GSK805 did not alter ILC3 frequencies (Fig. 4b) , production of IL-22 (Fig. 4c) or production of the proinflammatory cytokine TNF (Fig. 4d) . In contrast, in vitro cultures with GSK805 showed lower frequencies of CD4 + IL-17A + and CD4 + IL-22 + T cells (Fig. 4e,f) than those with DMSO. Culture with GSK805 led to a decrease in IL-17A + and IL-22 + T H 17 cells in cell suspensions from 8 out of 10 pediatric individuals with Crohn's disease (Fig. 4g) , did not influence the frequency of IFN-γ + T cells (Fig. 4h) and resulted in similar or higher frequencies of IL-17A + and IL-22 + ILC3s (Fig. 4i) . We obtained similar data with another ROR-γt inhibitor, digoxin 25 (Supplementary Fig. 9 ). Collectively, these results demonstrate that transient in vitro inhibition of ROR-γt in cells isolated from people with IBD selectively limits T H 17 cells.
Subsets of ILCs and CD4 + helper T cells have remarkably similar transcriptional profiles and effector cytokine responses yet can promote different functions in the context of immunity, inflammation and tissue repair [1] [2] [3] 11, 38 . Therefore, therapeutically targeting conserved pathways in the context of chronic inflammatory disease has the potential to influence both arms of the immune system and could, in addition to limiting a pathologic response, hinder beneficial responses that mediate protective immunity or tissue repair. This may account for offtarget consequences in patients with IBD treated with biologic therapies that broadly inhibit cytokine-cytokine receptor interactions, as in the anti-IL-17 clinical trials that resulted in increased infections or worsened disease [15] [16] [17] 39 . Here we uncover an unexpected cellular mechanism by which transient inhibition of the transcription factor ROR-γt allows for selective targeting of adaptive T H 17 cells without influencing protective ILC3 responses, both in mice and in human tissues cultured in vitro. These data provoke a challenge to the understanding of the modular effects of lineage-specifying transcription factors in the maintenance and function of innate versus adaptive lymphocytes and identify ROR-γt inhibition as an attractive future therapeutic approach to treat IBD and other chronic inflammatory diseases.
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